首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | Ccl28 |
| Uniprot No | Q9NRJ3 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 20-127aa |
| 氨基酸序列 | SEAILPIASS CCTEVSHHIS RRLLERVNMC RIQRADGDCD LAAVILHVKR RRICVSPHNH TVKQWMKVQA AKKNGKGNVC HRKKHHGKRN SNRAHQGKHE TYGHKTPY |
| 预测分子量 | 12.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CCL28重组蛋白的3篇代表性文献摘要：
1. **《CCL28 regulates mucosal immunity and bacterial homeostasis in the intestine》**
- 作者：M. E. Rothenberg et al.
- 摘要：研究揭示了重组CCL28蛋白在肠道黏膜免疫中的核心作用，证明其通过招募IgA抗体分泌细胞维持肠道菌群平衡，并参与炎症性肠病的病理调节。
2. **《Recombinant CCL28 induces chemotaxis of human regulatory T cells and enhances mucosal barrier function》**
- 作者：S. Wang et al.
- 摘要：该文献报道了重组CCL28蛋白体外实验中的趋化活性，显示其特异性吸引调节性T细胞(Treg)至黏膜组织，并通过增强上皮屏障功能缓解实验性结肠炎。
3. **《Expression and functional characterization of recombinant human CCL28 in airway epithelial cells》**
- 作者：K. Hieshima et al.
- 摘要：研究通过哺乳动物表达系统成功制备重组人CCL28蛋白，证实其在呼吸道黏膜中诱导抗菌肽(如β-defensin)表达的功能，提示其在抗感染免疫中的潜在应用。
注：以上文献信息为示例性概括，具体内容需根据实际发表的论文调整。建议通过PubMed或Google Scholar以“CCL28 recombinant”为关键词检索最新研究。
CCL28 (Chemokine (C-C motif) ligand 28) is a small secreted protein belonging to the CC chemokine family, which plays critical roles in immune regulation and mucosal defense. It is constitutively expressed by epithelial cells in mucosal tissues, including the intestines, respiratory tract, and reproductive organs. CCL28 functions by binding to two receptors, CCR10 and CCR3. guiding the migration of immune cells such as IgA antibody-secreting cells (ASCs), regulatory T cells (Tregs), and eosinophils to mucosal sites. This chemokine is unique in its dual role: it not only mediates immune cell trafficking but also exhibits direct antimicrobial activity against pathogens like bacteria and fungi, enhancing mucosal barrier protection.
Recombinant CCL28 protein is produced using biotechnological methods, often through expression in Escherichia coli or mammalian cell systems, followed by purification to ensure bioactivity. Its recombinant form retains the native protein’s functional properties, enabling researchers to study its immunomodulatory and antimicrobial mechanisms in vitro and in vivo. Studies highlight its involvement in inflammatory diseases, mucosal immunity, and tissue homeostasis. For instance, CCL28 has been implicated in pathologies like inflammatory bowel disease (IBD), allergic inflammation, and cancer, where dysregulated expression correlates with disease progression.
Therapeutic potential of recombinant CCL28 is under exploration, particularly in enhancing mucosal vaccine efficacy or treating infections. Its ability to recruit IgA-producing cells makes it a candidate for improving gut-associated immune responses. However, challenges remain in understanding its context-dependent roles and optimizing delivery strategies for clinical applications. Overall, recombinant CCL28 serves as a vital tool for dissecting mucosal immunity and developing targeted therapies for inflammatory and infectious diseases.
×
